[Therapy of atypical hyperplasia and adenocarcinoma of the endometrium with the combination of progestins and anticoagulants].
The data on clinical trials of newly-developed hormonotherapy of atypical hyperplasia (AH) and cervical adenocarcinoma (CAC) are presented. The study included 34 patients with histologically--confirmed AH and 86--CAC (stage I-II and III-IV). All patients were given preoperative "shock therapy" with a combination of progestins and anticoagulants: 500 mg, i.v., 10 days--(AH) and well-differentiated cell CAC; 20 days--moderately- and poorly-differentiated cell CAC. Total dose was 5 g and 10 g, respectively. Fibrolysin, pelentan and aspirin (antiaggregant of thrombocytes) were used as anticoagulants. For comparison, identical numbers of AH and CAC patients received similar preoperative progestin therapy without anticoagulants. The study was randomized. Hormonal pathomorphosis in tumor was identified after surgery and relevant characteristics of bioptical and resected material were compared. It was found that hormonotherapy used in conjunction with anticoagulants reinforced significantly all features of hormonal pathomorphosism both in AH and CAC stage I-II while, in well-differentiated cell adenocarcinoma, the difference from control was significant (p < 0.05).
Adamian
R T
RT
V.A. Fanarjyan Center for Cancer Research, Ministry of Health of the Republic of Armenia, Yerevan.
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000925:Anticoagulants / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016889:Endometrial Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004717:Endometrium / Q000473:pathology*; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use; D006965:Hyperplasia / Q000188:drug therapy; D017258:Medroxyprogesterone Acetate / Q000627:therapeutic use; D009367:Neoplasm Staging; D045167:Progesterone Congeners / Q000627:therapeutic use*; D016896:Treatment Outcome
D000925:Anticoagulants; D018931:Antineoplastic Agents, Hormonal; D004965:Estrogen Antagonists; D006908:Hydroxyprogesterones; D045167:Progesterone Congeners; D000077713:17 alpha-Hydroxyprogesterone Caproate; D017258:Medroxyprogesterone Acetate